OTCMKTS:BIXT

Bioxytran News Headlines

$0.17
-0.01 (-5.56 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.11
$0.17
50-Day Range
$0.07
$0.18
52-Week Range
$0.00
$0.33
Volume4,350 shs
Average Volume5,025 shs
Market Capitalization$17.13 million
P/E RatioN/A
Dividend YieldN/A
Beta-6.81

Headlines

Bioxytran (OTCMKTS BIXT) News Headlines Today

SourceHeadline
Bioxytran (OTCMKTS:BIXT) Trading Up 5.9%Bioxytran (OTCMKTS:BIXT) Trading Up 5.9%
americanbankingnews.com - May 7 at 12:30 AM
Bioxytran (OTCMKTS:BIXT) Trading 157.1% Higher Bioxytran (OTCMKTS:BIXT) Trading 157.1% Higher
americanbankingnews.com - April 16 at 12:40 AM
Bioxytran, Inc. (BIXT)Bioxytran, Inc. (BIXT)
finance.yahoo.com - November 3 at 5:55 PM
Bioxytran Licenses Novel Viral Inhibitor for COVID-19 PatientsBioxytran Licenses Novel Viral Inhibitor for COVID-19 Patients
finance.yahoo.com - September 21 at 9:18 AM
Bioxytran to Internally Develop Novel Carbohydrate Galectin Inhibitor to Eliminate COVID-19 in PatientsBioxytran to Internally Develop Novel Carbohydrate Galectin Inhibitor to Eliminate COVID-19 in Patients
finance.yahoo.com - September 21 at 9:18 AM
Bioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in PatientsBioxytran Releases Details on a Novel Carbohydrate Galectin Inhibitor designed to Eliminate COVID-19 in Patients
finance.yahoo.com - September 21 at 9:18 AM
Bioxytran Published A Surrogate Marker for ARDS and Stroke PatientsBioxytran Published A Surrogate Marker for ARDS and Stroke Patients
finance.yahoo.com - September 21 at 9:18 AM
This page was last updated on 5/9/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.